Vascular signaling through G protein-coupled receptors: New concepts

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 2, 2009, Pages 153-159

  Ushio Fukai, Masuko ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Endothelial cells; G protein coupled receptor; Nicotinamide adenine dinucleotide phosphate oxidase; Nitric oxide; Reactive oxygen species; Redox signaling; S nitrosothiols; S nitrosylation; Vascular smooth muscle cells

Indexed keywords

BETA ARRESTIN; DYNAMIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; GUANOSINE TRIPHOSPHATASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S NITROSOTHIOL;

ARTICLE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL MIGRATION; ENDOCYTOSIS; GENE EXPRESSION; HUMAN; INTERNALIZATION; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; DYNAMINS; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HUMANS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; S-NITROSOTHIOLS; SIGNAL TRANSDUCTION;

EID: 63849241819     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283252efe     Document Type: Article

References (63)

1. Drake MT, Shenoy SK, Lefkowitz RJ. Trafficking of G protein-coupled receptors. Circ Res 2006; 99:570-582.
2. Rerter E, Lefkowrtz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 2006; 17:159-165.
3. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev 2002; 3:639-650.
4. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW, Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997; 29:366-373.
5. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86:494-501.
6. Lambeth JD, Cheng G, Arnold R, Edens WA. Novel homologs of gp91 phox. Trends Biochem Sci 2000; 25:459-461.
7. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 2000; 97:8010-8014.
8. Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res 2006; 71:289-299.
9. Lambeth JD. Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) oxidases. Curr Opin Hematol 2002; 9:11-17.
10. Lassegue B, Sorescu D, Szocs K, et al. Novel gp91(phox) homologues in vascular smooth muscle cells: noxl mediates angiotensin ll-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88:888-894.
11. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006; 71:247-258.
12. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97.
13. Ushio-Fukai M, Griendling KK, Becker PL, et al. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21:489-495.
14. Eguchi S, Iwasaki H, Hirata Y, et al. Epidermal growth factor receptor is indispensable for c-Fos expression and protein synthesis by angiotensin II. Eur J Pharmacol 1999; 376:203-206.
15. Harder T, Simons K. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 1997; 9:534-542.
16. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J Biol Chem 1998; 273:5419-5422.
17. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev 2000; 1:31-39.
18. Quest AF, Leyton L, Parraga M. Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease. Biochem Cell Biol 2004; 82:129-144.
19. Vilhardt F, van Deurs B. The phagocyte NADPH oxidase depends on cholesterol-enriched membrane microdomains for assembly. Embo J 2004; 23:739-748.
20. Zhang AY, Yi F, Zhang G, et al. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension 2006; 47:74-80.
21. Callera GE, Montezano AC, Yogi A, et al. Vascular signaling through cholesterol-rich domains: implications in hypertension. Curr Opin Nephrol Hypertens 2007; 16:90-104.
22. Hilenski LL, Clempus RE, Quinn MT, et al. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24:677-683.
23. Zuo L, Ushio-Fukai M, Ikeda S, et al. Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. Arterioscler Thromb Vasc Biol 2005; 25:1824-1830.
24. Zuo L, Ushio-Fukai M, Hilenski LL, Alexander RW. Microtubules regulate angiotensin II type 1 receptor and Rac1 localization in caveolae/lipid rafts: role in redox signaling. Arterioscler Thromb Vasc Biol 2004; 24:1223-1228.
25. Ushio-Fukai M, Zafari AM, Fukui T, et al. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin ll-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271:23317-23321.
26. Zafari AM, Ushio-Fukai M, Akers M, et al. Role of NADH/NADPH oxidase-derived H202 in angiotensin ll-induced vascular hypertrophy. Hypertension 1998; 32:488-495.
27. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell 2005; 121:667-670.
28. Lee SR, Kwon KS, Kim SR, Rhee SG. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem 1998; 273:15366-15372.
29. Finkel T. Signal transduction by reactive oxygen species in nonphagocytic cells. J Leukoc Biol 1999; 65:337-340.
30. Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003; 28:509-514.
31. 2 with fluorescein-conjugated iodoacetamide and antibodies to fluorescein. FEBS Lett 1998; 440:111-115.
32. Tabet F, Schiffrin EL, Callera GE, et al. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res 2008; 103:149-158.
33. Caselli A, Mazzinghi B, Camici G, et al. Some protein tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1. Biochem Biophys Res Commun 2002; 296:692-697.
34. Hess DT, Matsumoto A, Kim SO, et al. Protein S-nitrosylation: purview and parameters. Nat Rev 2005; 6:150-166.
35. Kokkola T, Savinainen JR, Monkkonen KS, et al. S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner. BMC Cell Biol 2005; 6:21.
36. Chung KK, Thomas B, Li X, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (New York, NY) 2004; 304:1328-1331.
37. Huang Y, Man HY, Sekine-Aizawa Y, et al. S-nitrosylation of N-ethylmaleimide sensitive factor mediates surface expression of AMPA receptors. Neuron 2005; 46:533-540.
38. Jaffrey SR, Erdjument-Bromage H, Ferris CD, et al. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 2001; 3:193-197.
39. Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364:626-632.
40. Adam L, Bouvier M, Jones TL. Nitric oxide modulates beta(2)-adrenergic receptor palmitoylation and signaling. J Biol Chem 1999; 274:26337-26343.
41. Leclerc PC, Lanctot PM, Auger-Messier M, et al. S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin II. Br J Pharmacol 2006; 148:306-313.
42. Sun J, Steenbergen C, Murphy E. S-nitrosylation: NO-related redox signaling to protect against oxidative stress. Antioxid Redox Signal 2006; 8:1693-1705.
43. Ostrom RS, Bundey RA, Insel PA. Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes. J Biol Chem 2004; 279:19846-19853.
44. Sun J, Picht E, Ginsburg KS, et al. Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alphal subunit and reduced ischemia/reperfusion injury. Circ Res 2006; 98:403-411.
45. Whalen EJ, Johnson AK, Lewis SJ. Beta-adrenoceptor dysfunction after inhibition of NO synthesis. Hypertension 2000; 36:376-382.
46. Que LG, Liu L, Yan Y, et al. Protection from experimental asthma by an endogenous bronchodilator. Science (New York, NY) 2005; 308:1618-1621.
47. Gow AJ, Chen Q, Hess DT, et al. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem 2002; 277:9637-9640.
48. Liu L, Yan Y, Zeng M, et al. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 2004; 116:617-628.
49. Nozik-Grayck E, McMahon TJ, Huang YC, et al. Pulmonary vasoconstriction by serotonin is inhibited by S-nitrosoglutathione. Am J Physiol Lung Cell Mol Physiol 2002; 282:L1057-L1065.
50. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science (New York, NY) 2005; 308:512-517.
51. Nozik-Grayck E, Whalen EJ, Stamler JS, et al. S-nitrosoglutathione inhibits alphal-adrenergic receptor-mediated vasoconstriction and ligand binding in pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2006; 290:L136-L143.
52. Wang G, Moniri NH, Ozawa K, et al. Nitric oxide regulates endocytosis by S-nitrosylation of dynamin. Proc Natl Acad Sci U S A 2006; 103:1295-1300.
53. Kang-Decker N, Cao S, Chatterjee S, et al. Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2. J Cell Sci 2007; 120:492-501.
54. Whalen EJ, Foster MW, Matsumoto A, et al. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell 2007; 129:511-522.
55. 2-AR into the clathrin-based endocytotic pathway, which in turn denitrosylates β-arrestin 2.
56. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006; 46:235-276.
57. Lin FT, Krueger KM, Kendall HE, et al. Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated by phosphorylation/ dephosphorylation of beta-arrestin 1. J Biol Chem 1997; 272:31051-31057.
58. Lin FT, Miller WE, Luttrell LM, Lefkowitz RJ. Feedback regulation of betaarrestinl function by extracellular signal-regulated kinases. J Biol Chem 1999; 274:15971-15974.
59. Lin FT, Chen W, Shenoy S, et al. Phosphorylation of beta-arrestin2 regulates its function in internalization of beta(2)-adrenergic receptors. Biochemistry 2002; 41:10692-10699.
60. Liu S, Premont RT, Kontos CD, et al. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005; 11:952-958.
61. Lefkowitz RJ, Rajagopal K, Whalen EJ. New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell 2006; 24:643-652.
62. Rajagopal K, Whalen EJ, Violin JD, et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A 2006; 103:16284-16289.
63. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25:29-38.